Efficacy and Safety of the Bruton's Tyrosine Kinase Inhibitor Evobrutinib for Relapsing Multiple Sclerosis Over 3.5 Years of Treatment: An Ongoing Phase II Open-Label ExtensionX. Montalban,J. S. Wolinsky,D. L. Arnold,M. S. Weber, K. Piasecka-Stryczynska,D. Tomic, A. Seitzinger,H. GuehringNEUROLOGY（2023）引用 0|浏览10暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
